Amneal Pharmaceuticals, Inc. (FRA:2DT)
Germany · Delayed Price · Currency is EUR | Market Cap | 3.47B +62.2% |
| Revenue (ttm) | 2.64B +7.6% |
| Net Income | 105.91M |
| EPS | 0.32 |
| Shares Out | n/a |
| PE Ratio | 32.72 |
| Forward PE | 11.14 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 10.40 |
| Previous Close | 10.70 |
| Day's Range | 10.40 - 10.60 |
| 52-Week Range | 6.15 - 12.60 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 7, 2026 |
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and res... [Read more]
News
Amneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026
BRIDGEWATER, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), today announced that Chirag Patel, Co-Chief Executive and President, will ...
Amneal Pharmaceuticals price target raised to $16 from $15 at Barclays
Barclays analyst Glen Santangelo raised the firm’s price target on Amneal Pharmaceuticals (AMRX) to $16 from $15 and keeps an Overweight rating on the shares. The firm says it has…
Amneal Pharmaceuticals reports Q1 EPS 27c, consensus 17c
Reports Q1 revenue $722.52M, consensus $716.78M. “Amneal delivered a very strong start to 2026, reflecting the strength of our diversified business and multiple growth drivers across the portfolio. Ou...
Amneal Pharmaceuticals backs FY26 adjusted EPS view 95c-$1.05, consensus $1.00
Backs FY26 revenue view $3.05B-$3.15B, consensus $3.1B. Backs FY26 adjusted EBITDA view $740M-$770M. Backs FY26 capital expenditures view $110M.
Amneal Reports First Quarter 2026 Financial Results
‒ Q1 2026 Net Revenue of $723 million ; GAAP Net Income of $62 million ; Diluted Income per Share of $0.19 ‒ ‒ Adjusted EBITDA of $202 million ; Adjusted Diluted EPS of $0.27 ‒ ‒ No Change from Preli...
Amneal Pharmaceuticals Transcript: AGM 2026
The meeting was conducted virtually, with all director nominees elected and all proposals approved. No questions were raised by stockholders, and official voting results will be announced after verification.
Amneal Pharmaceuticals Proxy statement: Proxy filing
Amneal Pharmaceuticals filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Amneal Pharmaceuticals Proxy statement
Amneal Pharmaceuticals filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
Amneal Pharmaceuticals Earnings Call Transcript: Q1 2026
Announced acquisition of Kashiv BioSciences, creating a global biosimilars leader with a robust pipeline and strong Q1 results. Raised 2026 guidance, with biosimilars expected to drive significant revenue and margin growth through 2030.
Amneal Pharmaceuticals Slides: Q1 2026
Amneal Pharmaceuticals has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 22, 2026.
Amneal Pharmaceuticals Quarterly report: Q1 2026
Amneal Pharmaceuticals has published its Q1 2026 quarterly earnings report on April 22, 2026.
Amneal Pharmaceuticals Earnings release: Q1 2026
Amneal Pharmaceuticals released its Q1 2026 earnings on April 22, 2026, summarizing the period's financial results.
Amneal Pharmaceuticals Proxy statement: Proxy filing
Amneal Pharmaceuticals filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
Amneal Pharmaceuticals Proxy statement: Proxy filing
Amneal Pharmaceuticals filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
Amneal Pharmaceuticals Proxy statement: Proxy filing
Amneal Pharmaceuticals filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
Amneal Pharmaceuticals Proxy statement: Proxy filing
Amneal Pharmaceuticals filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
Amneal Pharmaceuticals Proxy statement: Proxy filing
Amneal Pharmaceuticals filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
Amneal Pharma to buy Kashiv BioSciences in $1.1 billion deal
Amneal Pharmaceuticals has agreed to acquire biopharma firm Kashiv BioSciences in a cash-and-stock deal worth up to $1.1 billion that will expand the drugmaker's biosimilars business.
Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader
PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv”), today announced that it has entered into a definitive agreement to be acquired by Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“A...
Amneal Pharmaceuticals raises FY26 adjusted EPS view to 95c-$1.05 from 93c-$1.03
Raises FY26 revenue to $3.05B-$3.15B from $3.05B-$3.15B. Consensus is for FY26 EPS 99c and for revenue $3.1B. Reaffirms FY26 CapEx view $110M.
Amneal Pharmaceuticals to acquire Kashiv BioSciences
Amneal Pharmaceuticals (AMRX) announced that it has entered into a definitive agreement to acquire 100% of Kashiv BioSciences, in a transaction with consideration that includes $375M of cash and $375M...
Amneal Pharmaceuticals reports Q1 adjusted EPS 27c, consensus 17c
Reports Q1 revenue $723M, consensus $720.52M. “Amneal delivered a very strong start to 2026, reflecting the strength of our diversified business and multiple growth drivers across the portfolio. Our S...
Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance
– Acquisition Positions Amneal to Capitalize on $300B+ Global Biologics LOE Opportunity – – Transaction Accelerates Growth Profile and Diversification – – Preliminary Q1 Results Reflect Continued Grow...
Amneal announces additional interim Phase 4 ELEVATE-PD study results
Amneal Pharmaceuticals (AMRX) announced new positive interim results from its ongoing Phase 4 ELEVATE-PD study, presented at the 2026 American Academy of Neurology, AAN. The first 111 patients evaluat...
Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson's Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®
Phase 4 ELEVATE-PD interim data (n=111) demonstrated clinically meaningful, consistent benefits of CREXONT across all prior treatment groups Demonstrated substantial increases in daily “Good On” time,...